FAVIRAB

Indications

• Schizophrenia
• Schizoaffective disorder
• Bipolar disorder
• Severe depression (as an adjunctive treatment)

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric populations, as dosing may differ significantly from adults.

Adults: Refer to specific clinical guidelines and patient factors for appropriate dosing, as doses may vary based on individual response and the specific formulation used.

Mechanism of action

Arietans acts as an antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors. This dual action helps to balance the levels of these neurotransmitters in the brain, reducing the symptoms of psychosis and stabilizing mood. The blockade of dopamine receptors helps alleviate positive symptoms of schizophrenia, while the serotonin receptor antagonism may address negative symptoms and improve overall mood.

Pharmacodynamics

The pharmacodynamic profile of Arietans includes its ability to reduce dopaminergic hyperactivity associated with psychotic symptoms. By antagonizing dopamine receptors, Arietans helps to mitigate symptoms such as hallucinations and delusions. Additionally, its action on serotonin receptors may contribute to improved mood and emotional regulation, making it beneficial for patients with both positive and negative symptoms of schizophrenia.

Pharmacokinetics

Arietans is well absorbed after oral administration, with peak plasma concentrations occurring within a few hours. It undergoes extensive hepatic metabolism, primarily via the cytochrome P450 system, leading to the formation of active metabolites. The drug has a half-life that allows for once-daily dosing in many cases. It is primarily excreted in urine, with a smaller fraction eliminated in feces. The pharmacokinetics can be affected by factors such as liver function and potential drug interactions.

Pregnancy

Consult with a healthcare provider for use during pregnancy.

Breast-feeding

Consult with a healthcare provider for use while breastfeeding.

Storage

Store at room temperature, away from moisture and heat.

Indications

• Management of Bitis snake bites
• Emergency treatment of envenomation
• Supportive care for symptoms of envenomation

Dosage

Children: For envenomation from Bitis species, immediate medical attention is required. Antivenom specific to the species involved should be administered, with dosing guided by weight and severity of symptoms

Adults: For envenomation from Bitis species, immediate medical attention is required. Antivenom specific to the species involved should be administered as per clinical guidelines. Dosing should be guided by the severity of symptoms and clinical protocols.

Mechanism of action

The venom of Bitis snakes primarily acts through the disruption of hemostasis and the induction of local tissue damage. It contains phospholipases, metalloproteinases, and neurotoxins that affect blood coagulation and nerve function. The metalloproteinases degrade proteins in the extracellular matrix, leading to tissue necrosis, while the phospholipases disrupt cell membranes, contributing to inflammation and pain.

Pharmacodynamics

The pharmacodynamics of Bitis venom involves a combination of anticoagulant, pro-inflammatory, and cytotoxic effects. The venom can cause a rapid onset of pain and swelling at the bite site, followed by systemic effects such as hypotension, coagulopathy, and shock. The severity of symptoms can vary based on the species of Bitis, the quantity of venom injected, and the location of the bite.

Pharmacokinetics

Due to the nature of venom, traditional pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion do not apply. The effects of Bitis venom are immediate and localized at the site of envenomation, with systemic effects developing rapidly. The venom components may be metabolized by the body, but specific pharmacokinetic data on the elimination of venom components are limited.

Pregnancy

There is limited data on the safety of Bitis during pregnancy. Caution should be exercised.

Breast-feeding

It is unknown whether Bitis is excreted in human milk. Caution is advised while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Management of Echis snakebite envenomation
• Administration of antivenom in cases of severe envenomation
• Supportive care for systemic complications related to snakebite

Dosage

Children: Refer to local guidelines for the appropriate dosing of antivenom in cases of Echis envenomation in children.

Adults: Refer to local guidelines for the appropriate dosing of antivenom in cases of Echis envenomation.

Mechanism of action

The venom of Echis snakes contains various enzymes and proteins that disrupt hemostasis, leading to the activation of coagulation pathways and causing local tissue necrosis. The venom's components can include phospholipases, metalloproteinases, and neurotoxins, which together result in complex interactions with blood components and endothelial cells.

Pharmacodynamics

Echis venom's pharmacodynamic effects are characterized by rapid onset of symptoms following envenomation, including pain, swelling, and potential necrosis at the bite site. Systemic effects may include bleeding diathesis due to coagulopathy, hypotension, and acute kidney injury in severe cases. The clinical manifestation depends on the species of the snake, the amount of venom injected, and the location of the bite.

Pharmacokinetics

The pharmacokinetics of Echis venom are not well-studied in the same way as traditional drugs. However, the effects of the venom are rapid, generally occurring within minutes to hours post-envenomation. The venom components are metabolized and cleared from the body over days, but the clinical effects can persist for a prolonged period, especially if significant tissue damage or coagulopathy occurs.

Adverse effects

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Headache
• Dizziness
• Hypotension
• Allergic reactions

Precautions

• Use with caution in patients with a history of allergic reactions to snake venoms.
• Monitor for signs of anaphylaxis.
• Caution in patients with coagulopathy or those on anticoagulant therapy.

Pregnancy

Echis venom should be avoided during pregnancy due to potential risks to the fetus.

Breast-feeding

Caution is advised as the effects on breastfeeding infants are not well studied.

Storage

Store in a cool, dry place, away from direct sunlight and heat.

Indications

• Partial seizures in adults and children
• Postherpetic neuralgia
• Neuropathic pain
• Restless leg syndrome

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines based on the condition being treated.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Gabapentin binds to the α2δ subunit of voltage-gated calcium channels in the central nervous system. This binding inhibits excitatory neurotransmitter release, thereby reducing neuronal excitability and preventing the onset of seizures. Additionally, it is believed to enhance the synthesis of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid), contributing to its analgesic properties.

Pharmacodynamics

Gabapentin exhibits a dose-dependent effect on the central nervous system. It is effective in reducing seizure frequency in patients with partial seizures and alleviating neuropathic pain. The drug does not significantly affect the metabolism of other medications, making it a favorable option in polypharmacy scenarios. Its analgesic effects are attributed to the modulation of calcium channels and enhancement of GABAergic transmission.

Pharmacokinetics

Gabapentin is absorbed from the gastrointestinal tract with a bioavailability that decreases as the dose increases. Peak plasma concentrations are typically reached within 2 to 3 hours post-dose. The drug is not extensively metabolized and is primarily eliminated unchanged via the kidneys. Its half-life ranges from 5 to 7 hours, necessitating multiple daily doses for optimal effectiveness.

Pregnancy

Gabonica should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. There is limited data on its safety in pregnant women.

Breast-feeding

Caution is advised when administering Gabonica to breastfeeding women. The effects on nursing infants are unknown.

Storage

Store Gabonica in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Refer to specific clinical guidelines and references for dosage information, as it is not provided in established sources.

Adults: Refer to specific clinical guidelines and references for dosage information, as it is not provided in established sources.

Mechanism of action

The exact mechanism of action for leucogaster is not well-documented in available literature. However, if it is associated with certain pharmacological actions, it may interact with specific receptors or enzymatic pathways, potentially influencing physiological processes.

Pharmacodynamics

Pharmacodynamics for leucogaster is not specifically established due to the lack of comprehensive data. Generally, pharmacodynamics involves understanding how a drug affects the body, including its therapeutic effects and side effects, which can be influenced by the drug's binding affinity to receptors and its concentration at the site of action.

Pharmacokinetics

Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and excretes a drug. For leucogaster, specific pharmacokinetic parameters such as bioavailability, half-life, volume of distribution, and clearance are not readily available, highlighting the need for further research and clinical studies.

Pregnancy

There is no sufficient data on the safety of leucogaster in pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether leucogaster is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Dosage

Children: Specific dosage recommendations for paediatrics cannot be provided due to the absence of established dosing guidelines.

Adults: Specific dosage recommendations for adults cannot be provided due to the absence of established dosing guidelines.

Mechanism of action

The precise mechanism of action for ocellatus is not well-documented in established sources. Any pharmacological activity may depend on its chemical structure and interactions with biological targets, which require further elucidation through research.

Pharmacodynamics

The pharmacodynamics of ocellatus are not well-characterized. Understanding how it affects cellular and physiological processes would typically require detailed studies, including receptor binding profiles and dose-response relationships.

Pharmacokinetics

Pharmacokinetic data for ocellatus is currently unavailable. Generally, pharmacokinetics would involve the study of absorption, distribution, metabolism, and excretion, but specific studies for this compound are lacking.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and the benefits outweigh the risks.

Breast-feeding

Caution is advised when administering to breastfeeding mothers. Monitor for adverse effects in the infant.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Mechanism of action

Venoms exert their effects through various mechanisms, including enzymatic activity that disrupts cellular integrity, inhibition of neurotransmitter release, and modulation of ion channels. For example, neurotoxic venoms may block acetylcholine receptors at neuromuscular junctions, leading to paralysis. Other venoms can activate or inhibit specific receptors or pathways, resulting in pain, inflammation, or coagulation disturbances.

Pharmacodynamics

The pharmacodynamics of venom components depend on their specific targets and effects. Many venoms are designed to incapacitate prey quickly, with rapid onset of action. Effects may include paralysis, hemorrhage, or disruption of normal physiological functions. The potency and duration of action vary widely among different venoms and their constituent molecules.

Pharmacokinetics

Pharmacokinetics of venom components can vary significantly based on their structure and the route of exposure. After envenomation, the compounds may be rapidly absorbed into the bloodstream, leading to systemic effects. Metabolism typically occurs in the liver, and excretion can happen through urine or feces. The onset of action can be immediate, while the duration depends on the specific venom type and individual response.

Pregnancy

There is limited information on the use of venom during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when using venom while breastfeeding due to the unknown effects on the infant.

Storage

Store in a cool, dry place, away from direct sunlight. Specific storage conditions may vary depending on the formulation.